Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Colchicine  COVID-19 treatment studies for Colchicine  C19 studies: Colchicine  Colchicine   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 23% Improvement Relative Risk ICU time 40% c19colchicine.com Valerio Pascua et al. Colchicine for COVID-19 ICU Favors colchicine Favors control
Valerio Pascua, 65 patient colchicine ICU study: 23% lower mortality [p=0.6] and 40% lower ICU admission [p=0.03] https://c19p.org/valeriopascua
copied to clipboard
A multi-mechanism approach reduces length of stay in the ICU for severe COVID-19 patients
Valerio Pascua et al., PLOS ONE, doi:10.1371/journal.pone.0245025
7 Jan 2021    Source   PDF   Share   Tweet
Retrospective 65 ICU patients in the USA and Honduras, showing shorter ICU stay with combined treatment including colchicine,
LMWH, tocilizumab, dexamethasone, and methylprednisolone.
risk of death, 22.8% lower, RR 0.77, p = 0.60, treatment 5 of 35 (14.3%), control 12 of 30 (40.0%), NNT 3.9, adjusted per study, odds ratio converted to relative risk, multivariable.
ICU time, 39.9% lower, relative time 0.60, p = 0.03, treatment 35, control 30, adjusted per study, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Valerio Pascua et al., 1/7/2021, retrospective, multiple countries, multiple regions, peer-reviewed, 19 authors, study period 10 June, 2020 - 6 August, 2020, average treatment delay 6.1 days, this trial uses multiple treatments in the treatment arm (combined with LMWH, tocilizumab, dexamethasone, methylprednisolone) - results of individual treatments may vary.
All Studies   Meta Analysis
This PaperColchicineAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit